Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy

The phase III clinical trial of the novel molecular targeted agent (MTA) lenvatinib for patients with advanced hepatocellular carcinoma (HCC) (REFLECT trial) found that lenvatinib was non-inferior to sorafenib in overall survival. Recently, the efficacy of multiple MTAs, including lenvatinib, in pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sho, Takuya, Morikawa, Kenichi, Kubo, Akinori, Tokuchi, Yoshimasa, Kitagataya, Takashi, Yamada, Ren, Shigesawa, Taku, Kimura, Mugumi, Nakai, Masato, Suda, Goki, Natsuizaka, Mitsuteru, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713309/
https://www.ncbi.nlm.nih.gov/pubmed/35070043
http://dx.doi.org/10.4251/wjgo.v13.i12.2076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713309/
https://www.ncbi.nlm.nih.gov/pubmed/35070043
http://dx.doi.org/10.4251/wjgo.v13.i12.2076

Ejemplares similares